Here's why ASX 200 health insurance shares like Medibank are being trounced today

Investors are feeling a bit sick after the latest update.

| More on:
ASX share price movement represented by doctor pressing digitised screen with array of icons including one entitled health insurance,

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The S&P/ASX 200 Index (ASX: XJO) health insurance shares such as Medibank Private Ltd (ASX: MPL) are underperforming the index today for one key reason. At the moment, the Medibank share price is down 0.7%, while the ASX 200 is down 0.2%.

Unlike many other industries, how much money the private health insurance sector can make is somewhat controlled by the Federal Government.

The Australian Government ultimately approves the premium increases that the private health insurance businesses want to enact.

The next premium hikes could be elevated, with news breaking today of how much more Aussies may be paying.

Large premium increases requested

According to reporting by the Australian Financial Review, private health insurers are going to ask the Labor Government to increase premiums by twice as much as last time.

AFR sources with detailed knowledge of the discussions estimate that private health insurers will increase premiums by 5% to 6% in April, the largest increase since 2016.

Large insurers have given early estimates of costs, including forecasts of payments to private hospitals and medical treatment.

The NIB Holdings Limited (ASX: NHF) share price is currently down 0.9%, as one of the other major players in the space. The NIB CEO Mark Fitzgibbon said:

I expect (in the) longer run claims inflation will run at 4% to 6% and right now. That is keeping with what we have seen for 24 years when claims have generally grown at 5.5% per annum.

There has always been heavy scrutiny on premium increases as there always has been. Ultimately, we have to cover claims inflation like any insurer because if you don't eventually you go out of business.

Last time, Health Minister Mark Butler granted a premium increase that was about half of what private health funds, such as ASX 200 health insurance shares, had wanted.

The AFR reported that insurance businesses think premium increases should return to pre-COVID levels, considering the cost of treatment and the number of surgeries is rising again.

The newspaper noted that analysts and healthcare experts said it was "unlikely the government would approve an increase above 3%".

Terry Barnes, a health policy consultant and former adviser to the Howard government, said:

The government will be very nervous about anything more than 2% to 3%. The government of the days wants premiums to increase at the lowest possible rate and this year of all years will be running the ruler very closely over applications.

Medibank share price snapshot

Since the start of 2024, Medibank shares have risen 3.2%, compared to a rise of 8.8% for the ASX 200.

Created with Highcharts 11.4.3Medibank Private Ltd PriceZoom1M3M6MYTD1Y5Y10YALL31 Dec 202316 Oct 2024Zoom ▾Jan '24Feb '24Mar '24Apr '24May '24Jun '24Jul '24Aug '24Sep '24Oct '24Jan '24Jan '24Apr '24Apr '24Jul '24Jul '24Oct '24Oct '24www.fool.com.au

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 7 February 2025

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended NIB Holdings. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Sigma share price up 9% on first day of trading post-merger with Chemist Warehouse

It's a post-merger party for Sigma Healthcare shareholders today.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Up 135% in a year, why this ASX 200 healthcare stock is 'on track to become a truly great Australian success'

A leading fund manager expects more strong performance from this surging ASX 200 healthcare stock.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

With revenue up 9%, why does the NIB share price keep falling?

Will the ailing share price make a full recovery?

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Guess how much $5,000 invested in Sigma shares in December 2023 is worth now!

Sigma shares have soared over the past year alongside the merger with Chemist Warehouse.

Read more »

Woman with headphones on relaxing and looking at her phone happily.
Healthcare Shares

Everything you need to know about the latest CSL dividend

CSL's latest dividend should be turning investors' heads...

Read more »

thoughtful investor sitting at computer
Healthcare Shares

What are brokers saying about CSL shares after the selloff?

The biotech giant's shares hit a 52-week low yesterday. Is this a buying opportunity?

Read more »

A man looking at his laptop and thinking.
Earnings Results

CSL shares push higher despite 'mixed result with headline misses'

There were positives and negatives in the company's first half performance.

Read more »

Scientists working in the laboratory and examining results.
Earnings Results

CSL share price on watch amid $2.1b half year profit and dividend hike

Let's see how this biotech giant performed during the first half of FY 2025.

Read more »